Imagine your physician prescribes the medication best suited to treat your condition, and it costs less than other available treatments. Yet your insurance company refuses to cover it until you’ve tried and failed one or two more expensive drugs.
As a rheumatologist, I’ve seen variations of this scenario much too often. And despite the recent wave of Pharmacy Benefit Manager. (PBM) reforms, I worry we’re still missing the most important part of the equation: the patient.
Congress deserves credit for passing meaningful PBM reforms in the Consolidated Appropriations Act of 2026, and the Federal Trade Commission and Department of Labor have also taken important steps on rebate practices and employer transparency. These reforms largely address how money moves through our healthcare system, not whether patients can afford and access their medications.
Consider the Medicare Part D requirement that PBMs pass drug rebates to the health plan sponsor, not necessarily to patients. When the sponsor and PBM belong to the same vertically integrated corporation, we’re simply moving money from the left pocket to the right pocket, with no guarantee that patients pay a penny less at the pharmacy counter.
Step therapy, often called “fail first,” compounds this. For patients with rheumatoid arthritis and other inflammatory diseases, treatment delays can mean irreversible joint damage and disability. Non-medical switching creates similar problems when stable patients are forced to change medications because their drug is removed from the formulary — the list of drugs insurance will cover — or placed on a higher, more expensive tier. Patients should not have to justify a successful treatment simply because a new financial arrangement has been negotiated.
Another insurance and PBM tactic, copay accumulators, which prevent manufacturer copay assistance from counting toward patients’ out-of-pocket costs — are particularly harmful to patients with chronic diseases who cannot afford low-deductible plans. When assistance runs out midyear, patients may be unable to afford their medications and lose access to treatment.
The federal government has rejected copay maximizer and optimizer programs for its employees, yet millions of other Americans remain unprotected. A federal court restored the 2020 consumer protections in 2023, but federal regulators have failed to enforce them consistently. Why are patients still waiting for the government to enforce its own rules?
Drug pricing reform overall faces the same pitfall. Lower drug prices are an important goal. A lower price does not automatically translate into lower patient costs or better access. A lower-priced drug may be excluded from a formulary in favor of a higher-priced product that offers greater rebates or other financial advantages. For physician-administered medications, payment limits set below acquisition cost can leave providers unable to administer treatmentl, forcing a patient to travel, wait, or go without.
Vertical integration further complicates matters. The same corporation may own the insurer, PBM, group purchasing organization, specialty pharmacy and companies that distribute or private-label biosimilars. This creates an inherent conflict of interest when it profits from selling a drug, influences its formulary placement, determines what patients pay, and directs where prescriptions are filled. Transparency may expose these conflicts, but it doesn’t prevent patient harm.
So, what should Congress do next? It’s pretty straightforward.
—Protect patients from inappropriate step therapy and nonmedical switching.
—Strengthen formulary adequacy standards for Medicare Advantage.
—Ban copay accumulators and maximizers nationwide, with meaningful enforcement.
—Address conflicts of interest in vertically integrated insurers.
—Above all, make patient affordability and access central to every drug-pricing reform.
Success cannot be measured solely by rebates collected, fees disclosed or projected savings. The legislation passed this year was an important step, but only an opening salvo. Millions of Americans are still at the mercy of a system in which corporate executives hold the leverage to stand between them and their doctors.
Congress won a battle. The war for patients is far from over.













Madelaine A. Feldman | INSIDE SOURCES
Recent Articles
Prescott Regional Communications Center Earns Third Place Nationwide in T-Mobile Innovation in Community Competition
‘Art for Everyone’ Returns to Prescott
Prescott Valley Voters Shoot Down Local Propositions – Bill Williams
Arizona’s #1 Farmers Market Opens Its 13th Winter Season November 7